




This is the author’s final version of the work, as accepted for publication  
following peer review but without the publisher’s layout or pagination.  








Smart, L., Macdonald, S.P.J., Bosio, E., Fatovich, D., Neil, C. and Arendts, G. (2019) Bolus therapy with 3% hypertonic 
saline or 0.9% saline in emergency department patients with suspected sepsis: A pilot randomised controlled trial. 








Copyright: © 2019 Elsevier Inc 




Bolus therapy with 3% hypertonic saline or 0.9% saline in
emergency department patients with suspected sepsis: A pilot
randomised controlled trial
Lisa Smart, Stephen P.J. Macdonald, Erika Bosio, Daniel




To appear in: Journal of Critical Care
Please cite this article as: L. Smart, S.P.J. Macdonald, E. Bosio, et al., Bolus therapy with
3% hypertonic saline or 0.9% saline in emergency department patients with suspected
sepsis: A pilot randomised controlled trial, Journal of Critical Care, https://doi.org/
10.1016/j.jcrc.2019.03.009
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
















Bolus therapy with 3% hypertonic saline or 0.9% saline in emergency department 
patients with suspected sepsis: a pilot randomised controlled trial 
Lisa Smart
1,2,5












Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical 
Research, Perth, Australia 
2
Emergency Medicine, University of Western Australia, Perth, Australia 
3
Emergency Department, Royal Perth Hospital, Perth, Australia 
4
Emergency Department, Fiona Stanley Hospital, Perth, Australia 
5




Dr Lisa Smart 
Centre for Clinical Research in Emergency Medicine 
Level 6, MRF Building, Royal Perth Hospital 
Rear 50 Murray St. Perth, WA 6000, Australia 
Email: Lisa.smart@research.uwa.edu.au 
Phone: +618 9224 8458 
ORCID: 0000-0003-4776-2849 
 
Trial registration: ANZCTR.org.au, ACTRN12611001021965, Registered on 23
rd
 

















The results of this study were, in part, published in abstract form (Critical Care 2018, 
22(Suppl 1):P303) as a part of the International Symposium on Intensive Care and 
Emergency Medicine, Brussels, Belgium (March, 2018).  
 
Acknowledgements 
We thank Simon Brown, Shelley Stone and Trevelyan Edwards for their input into study 
design. This study was funded by the Jean Kahan Memorial Scholarship (Harry Perkins 
Institute of Medical Research) and the Centre for Clinical Research in Emergency Medicine. 
 
Declarations of interest: none 
 




Objective and design: Hypertonic saline administered during fluid resuscitation may 
mitigate endothelial glycocalyx (EG) shedding and inflammation. The objective of this pilot 
randomised controlled trial was to measure the effect of hypertonic saline, compared to 
isotonic saline on biomarkers of EG shedding and inflammation in emergency department 
patients with suspected sepsis. 
Methods: Patients received either 5 mL/kg of 3% saline (hypertonic group, n=34) or 10 
mL/kg of 0.9% saline (isotonic group, n=31). Serum biomarker concentrations of syndecan-1, 
hyaluronan, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, 
















were compared at baseline (T0), after fluid (T1), 3 hours (T3) and 12-24 hours (T24) later, as 
was serum osmolality, using linear mixed effects models.  
Results: The hypertonic group had significantly increased mean serum osmolality compared 
to the isotonic group at T1 (P<0.001) and T3 (P=0.004). Minor differences were found in 
some biomarker outcomes, including a decreased fold-change in syndecan-1 at T1 (P=0.012) 
and in interleukin-10 at T24 (P=0.006) in the isotonic group, compared to the hypertonic 
group.  
Conclusions: Although a single bolus of hypertonic saline increased serum osmolality, it did 
not reduce biomarkers of EG shedding or inflammation, compared to patients that received 
isotonic saline.  
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ED  Emergency department 
EG Endothelial glycocalyx 
ICU Intensive care unit 
IL  Interleukin 
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Sepsis is characterised by a dysregulated host response to an infection [1]. This can 
lead to microcirculatory alteration, reduced tissue perfusion and organ dysfunction. Current 
recommendations for improving perfusion in the early stages of treatment include bolus fluid 
administration, up to 30 mL/kg for patients with hypoperfusion [2]. However, patient fluid 
requirements and fluid responsiveness can be difficult to assess in regards to volume titration, 
and positive fluid balance has been associated with increased mortality in intensive care unit 
(ICU) patients with sepsis [3, 4].  
 
An association between large volumes of crystalloid and poorer outcomes in septic 
patients is currently an active area of investigation [5, 6, 3, 7]. One proposed mechanism for 
this association is shedding of the endothelial glycocalyx (EG), causing fluid extravasation 
and interstitial oedema [8]. Shedding of the EG precipitates endothelial and leucocyte 
activation, and increased vascular permeability [9-11]. Our recent work in patients with 
pneumonia has shown positive associations between circulating EG and neutrophil activation 
biomarker concentrations [12]. Increased EG shedding in patients with sepsis has also been 
associated with cumulative fluid volumes, degree of organ failure and mortality [13-20]. 
Therefore, strategies aimed at mitigating shedding of the EG, such as modification of current 
resuscitation practices, may improve outcomes for patients with sepsis.  
 
Hypertonic saline increases serum osmolality and draws water from the interstitium, 
therefore it may re-establish blood flow while avoiding administration of large volumes of 
fluid. In turn, this may reduce EG shedding and endothelial activation. Hypertonic saline has 
















activation and adhesion [21-30]. Studies in trauma patients have shown evidence that 
hypertonic saline reduced endothelial activation and inflammation, compared to isotonic 
crystalloid [31-34]. However, there is currently little information on the endothelial and 
immunomodulatory effects of hypertonic saline, compared to isotonic crystalloid, when used 
in adult patients with sepsis.  
 
In this randomised controlled pilot trial we sought to compare the effect of two initial 
fluid bolus strategies, 5 mL/kg of hypertonic saline or 10 mL/kg of isotonic saline, in adult 
patients with suspected infection meeting Systemic Inflammatory Response Syndrome 
(SIRS) criteria. We hypothesised that patients who received hypertonic saline would have an 
increased serum osmolality and reductions in biomarkers of endothelial activation and 
inflammation over time, compared to patients who received isotonic saline. We also 
hypothesised that hypertonic saline would reduce the volume of fluids subsequently given 





This study was approved by the Royal Perth Hospital Human Research Ethics 
Committee (HREC 2011-091) and was registered with the Australian and New Zealand 
Clinical Trials Registry (ACTRN12611001021965) before commencement. The Sepsis-
Saline Trial (SST) was a pragmatic, investigator-initiated, single-center, randomised 
controlled open-label pilot trial of adult patients presenting to the emergency department 
(ED) with suspected infection, who met SIRS criteria and required a fluid bolus as judged by 
















informed consent. Patients were randomised via password-protected web-based interface to 
receive either intravenous 3% saline (hypertonic group) or 0.9% saline (isotonic group). 
Patients were recruited between November, 2011 and April, 2015. The primary outcome of 
this study was fold-change in endothelial activation and inflammatory biomarker 
concentrations. Secondary outcomes included serum osmolality, volume of fluids 
administered and development of organ failure.  
 
Patients 
Patients admitted to the ED were included if they met 2 of 4 SIRS criteria 
(temperature >38 
o
C or <36 
o
C, heart rate >90 bpm, respiratory rate >20 bpm or white cell 
count >12 x10
9
/L or <4 x10
9
/L) as well as clinical suspicion of infection and a clinical 
requirement for fluid administration. Patients were excluded if there was a contraindication to 
fluid volume loading, a plasma sodium concentration <135 or >145 mmol/L, acidosis 
(venous pH<7.25), established renal failure (eGFR <45 mL/min/1.73m
2
), pregnancy, age <18 
years, patient deemed to receive palliative care only or they had received >500 mL total of 
pre-hospital crystalloid fluid.  Patients that required immediate resuscitation were also 
excluded, as research processes including the ethics committee requirement for informed 
patient consent may have delayed treatment. 
 
Intervention 
Patients were randomised to receive either 5 mL/kg of 3% saline or 10 mL/kg of 0.9% 
saline, to be given over less than 1 hour intravenously. Blinding of the study intervention was 
not possible due to the different volumes required. The dose of 0.9% saline was chosen to be 
consistent with the usual practice in the authors’ ED, with a maximum dose of 1000 mL total 
















one litre of 0.9% saline at a maximum dose of 600 mL. Any treatment given after the study 
fluid, including additional crystalloid fluid, was open-label and not restricted. All fluids given 
after enrolment were recorded, including volume and type of fluid, up until the last blood 
sampling time point.  
 
Data collection 
Heart rate, mean arterial blood pressure and haemoglobin concentration were 
collected from the medical records, aligned with the research blood sampling time points 
below. The Sequential Organ Failure Assessment (SOFA) score [35] was slightly modified 
for the ED setting (Table 1) and calculated from data collected during three time periods; 
during ED stay, on day 1 (first 24 hours in wards or ICU) and day 2 (second 24 hours in 
wards or ICU). A single clinician blinded to treatment allocation reviewed medical records 
and assigned a discharge diagnosis category of either ‘not infection’, ‘suspected infection’ or 
‘confirmed infection’, informed by review of diagnostic test results and subsequent clinical 
course. Charlson Comorbidity Score [36] was calculated from data at time of admission. 
 
Laboratory parameters 
Blood samples were taken prior to administration of the study fluid (T0), and 1 hour 
(T1), 3 hours (T3) and 12-14 hours after fluid administration (T24), and were chosen to be 
consistent with the sampling protocol of a parallel study [37]. Samples were collected into a 
serum clot tube then centrifuged at 3000 rpm at 4
o
C for 10 minutes. Serum was then 
aliquoted and stored at -80
o
C. Inflammatory biomarkers, neutrophil gelatinase-associated 
lipocalin and resistin, as well as glycocalyx biomarkers, syndecan-1 and hyaluronan, were 
measured using commercial enzyme-linked immunosorbent assay kits (R&D Systems, 
















and endothelial biomarkers, soluble intercellular adhesion molecule-1 and soluble vascular 
cell adhesion molecule-1, were measured using a commercial multiplex cytometric bead 
array kit (BD Biosciences, San Jose, CA, USA). Serum osmolality was measured by freezing 
point depression (6M Osmometer, Löser Messetechnik, Berlin, Germany).  
 
Statistical methods 
Due to the exploratory nature of this study and lack of previous data to inform 
potential differences, a power calculation to estimate sample size was not performed. 
Normality of data was assessed by visual inspection of histograms and Q-Q plots. Patient 
characteristics were summarised using number (percentage) for categorical variables, and 
median [Q1-Q3] or mean (95% confidence interval) for continuous variables depending on 
normality. Between-group differences for baseline characteristics were tested using linear 
regression for normally distributed continuous variables, Fisher’s exact test for dichotomous 
variables, negative binomial regression for count variables and Wilcoxon rank sum test for 
continuous variables not normally distributed. 
 
Changes in clinical variables from baseline were compared using linear random 
effects regression models. Volumes of fluid delivered between each time point were 
compared using Wilcoxon rank sum test. Biomarker concentrations were log-transformed to 
produce normal or approximately normal distributions and summarised using geometric 
mean (95% confidence interval). Comparisons of change in biomarker concentration over 
time were made using either linear random effects regression or Tobit random effects 
regression models. For each biomarker, change from T0 was expressed as fold-change (95% 
confidence interval). Patients that had completed research blood sampling at T24 were further 
















of patients with organ failure (SOFA score>0) (Table 1) was compared between groups using 
Fisher’s exact test for each time period. Hospital length of stay was compared between 
groups using Wilcoxon rank sum text.  
 
All analyses were performed using Stata 14 (College Station, TX, USA) with 





This study included 31 patients randomised to the isotonic group and 34 patients 
randomised to the hypertonic group (Figure 1). There were no significant differences between 
baseline characteristics (Table 2).  Of patients with confirmed infection, 21 had positive 
bacterial culture (13 in the isotonic group, 8 in the hypertonic group), 9 had infection 
confirmed on imaging results (3 in the isotonic group, 6 in the hypertonic group), and 4 
patients had positive viral serology results (2 in each group). The most frequent source of 
infection was lung (n=15), followed by urinary tract (n=15) and soft tissue (n=9). 
 
Change in biomarker concentrations over time  
Summarised biomarker concentrations and fold-change from T0 for each subsequent 
time point are presented in Table 4. There was a significantly decreased fold-change in 
syndecan-1 at T1 in the isotonic group, compared to the hypertonic group (P=0.012). There 
were no significant differences between the two groups in fold-change for hyaluronan, 
soluble intercellular adhesion molecule-1 or soluble vascular cell adhesion molecule-1 at any 

















There was a significantly decreased fold-change in IL-10 at T24 in the isotonic group, 
compared to the hypertonic group (P=0.006). Otherwise, there were no significant 
differences between the two groups in fold-change for inflammatory cytokines IL-6, IL-8, 
neutrophil gelatinase-associated lipocalin or resistin. Interferon-γ was below the detectable 
limit for 78% of samples. There was no significant difference in number of samples with 
measurable interferon-γ, versus unmeasurable, at any time point between the two groups 
(data not shown).  
 
Clinical variables  
Serum osmolality in participants in the hypertonic group was significantly increased 
from baseline at T1 (P<0.001) and T3 (P=0.004), compared to the isotonic group, but there 
was no significant difference between groups by T24 (P=0.59) (Figure 2). There were no 
significant changes from baseline between the two groups in heart rate, mean arterial blood 
pressure or haemoglobin concentration over time (Table 3).  
 
Fluids administered 
Only patients in the hypertonic group received 3% saline during the study period 
(Figure 3). The isotonic group received significantly more 0.9% saline and total volume of 
fluids between T0 and T1 (both P<0.001), compared to the hypertonic group, but there were 
no significant differences between groups in volume of 0.9% saline or total fluid volume 
administered between T1 to T3 (P=0.37, P=0.68, respectively) or T3 to T24 (P=0.94, 
P=0.14, respectively) (Figure 3). One patient in the hypertonic group reported pain above the 

















The most frequent fluid type administered after the study fluid was 0.9% saline. Eight 
patients in the isotonic group received an additional fluid type, compared to 3 patients in the 
hypertonic group (P=0.068). Fluid types other than 0.9% saline included compound sodium 
lactate, 4% succinylated gelatine and albumin solution.  
 
Clinical outcomes 
There were significantly more patients with cardiovascular failure on day 1 in the 
isotonic group, compared to the hypertonic group (P=0.014) (Table 5). On day 1, 4 patients 
in the isotonic group required at least 20 mL/kg of intravenous fluids to maintain blood 
pressure (n=1) and/or required vasopressor support (n=3) whereas none of the patients in the 
hypertonic group required either types of blood pressure support. Also, there were 
significantly more patients with haematologic failure in the isotonic group on day 1, 
compared to the hypertonic group (P=0.026), confluent with decreases in platelet count 
(Table 5). Event rate was too low for central nervous system and renal failure to be compared 
(data not shown).  
 
There was no significant difference in length of hospitalisation between the isotonic 
group (median 2.4 days, Q1-Q3 1.2-4.2) and hypertonic group (3.1 days, Q1-Q3 1.9-5.2) 
(P=0.26). Only one patient was admitted to the ICU (isotonic group) and only one patient 




This pilot study demonstrated that a single bolus of hypertonic saline given to ED 
















compared to a single bolus of isotonic saline. However, administration of hypertonic saline 
did not reduce biomarker concentrations of EG shedding, endothelial activation or 
inflammatory biomarker concentrations, though small differences were found in fold-change 
of syndecan-1 and IL-10 at isolated time points. These minor differences were considered of 
low relevance given the distribution of the raw biomarker data at each time point. 
Additionally, hypertonic saline did not significantly reduce the volume of subsequent 
crystalloid administered. 
 
Studies in trauma patients that have received hypertonic saline have found less 
leucocyte and endothelial activation, lower inflammatory cytokine concentrations and fewer 
post-operative infections, compared to isotonic crystalloid [31-34]. This effect has not been 
replicated thus far in patients with sepsis. Although one pilot study found that hypertonic 
saline reduced the volume of subsequent fluid administration [38], there were no significant 
differences in gene expression for inflammatory cytokines compared to an isotonic fluid [39]. 
These results are difficult to interpret as the fluids used in this study were combined with 
hydroxyethyl starch, known to suppress cytokine production [40-42].  
 
Lack of treatment effect observed in this study may have been due to only achieving a 
modest increase of ~10 mmol/kg in serum osmolality (Figure 3). A greater change in 
osmolality may have been required in order to mitigate inflammation. For the purpose of 
simplicity, studies that have measured osmolarity are described here as osmolality, with 
recognition that these measurements have slight differences. Previous studies demonstrating 
immunomodulatory effects of hypertonic saline in vitro have used concentrations of saline at 
an osmolality of ~340 mmol/kg or higher [26, 43, 21, 44, 22, 29, 45]. In animal models 
















minimum of ~325 to 350 mmol/kg within 1 hour of infusion [22, 46]. Lack of treatment 
effect in this study may also be due to the timing of hypertonic saline delivery in relation to 
injury. Two different studies support that hypertonic saline has little effect if given after 
leucocyte activation [23] or is delayed beyond the onset of inflammation [47]. This may 
negate the immunomodulatory effects of hypertonic saline in the setting of sepsis, whereby 
there is little opportunity to deliver a fluid intervention close to the time of illness onset.  
 
In this study, there was no difference in volumes of subsequent crystalloid 
administered, due to additional open-label administration of 0.9% saline to patients in the 
hypertonic group. We were unable to determine from clinical data in medical records what 
prompted further fluid administration but this may have been driven by lack of blinding and 
clinician bias against withholding 0.9% saline. This additional fluid administration may have 
blunted any treatment effect on biomarker outcomes. The other reason for lack of treatment 
effect may have been due to the relatively mild severity of illness of this cohort; a 
consequence of the HREC requirement to restrict the trial only to those who could provide 
written consent. It is possible that inclusion of sicker patients or stricter protocolisation of 
subsequent fluid administration may have yielded different results.  
 
Strengths of this study include delivery of the intervention fluid early in the treatment 
of suspected sepsis, as well as frequent blood sampling during initial patient stabilisation. 
This study demonstrates the feasibility of achieving hyperosmolality with a single dose of 3% 
saline, which has not been previously reported in this type of patient cohort. Patients in the 
hypertonic group also achieved similar blood volume expansion, based on no difference in 
haemoglobin concentration at T1, supporting the effect of hypertonic saline drawing fluid 
















illness in this patient cohort. Although the finding of more patients in the isotonic group 
having cardiovascular failure on day 1 of hospitalisation is provocative, the result may be 
coincidental in such a small sample size. This study would have also been strengthened by 
assessment of serum sodium, chloride and base excess concentrations, however lack of these 
measurements at T24 for most patients precluded this analysis. The biomarkers used in this 
study were chosen on the basis of previous work demonstrating their association with 
severity of sepsis [48, 13], however, broadening the spectrum of biomarker assessment may 
have been more informative. Given the small sample size, variations in baseline biomarker 
concentrations may have influenced the results, despite only statistically comparing fold-
change in biomarker concentrations. Recommendations for future research in this area 
include selection of patients with a higher severity of illness, blinding of the intervention 
fluid and protocolisation of subsequent fluid administration aimed at achieving clinical 
endpoints.  
 
In conclusion, delivery of a single bolus of 3% hypertonic saline in ED patients with 
suspected sepsis increased serum osmolality but did not reduce biomarkers of endothelial 
glycocalyx shedding, endothelial activation or inflammation, compared to patients that 
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Figure 1. Study flow chart 
Figure 2. Serum osmolality (mean, 95% confidence interval) in Emergency Department 
patients with suspected sepsis that received either 10 mL/kg of 0.9% NaCl (Isotonic) or 5 
mL/kg of 3% NaCl (Hypertonic) measured at baseline (T0), 1 hour after start of fluid 
intervention (T1), and then 3 hours (T3) and 12-24 hours (T24) later. Asterisks denote 
















Figure 3. Fluid volumes (median, interquartile range) of 3% NaCl, 0.9% NaCl and all 
crystalloid fluid delivered to Emergency Department patients with suspected sepsis that were 
randomised to receive either 10 mL/kg of 0.9% NaCl (Isotonic) or 5 mL/kg of 3% NaCl 


















Table 1. Modified Sequential Organ Failure Assessment score scheme for Emergency 
Department patients with suspected sepsis.  
 






>94% on 0.21 
<400 
<400 
>94% on 6 LPM 
<300 
<315 
<90% on >6 LPM 
<200 
<235 
+ resp support 
<100 
<150 
+ resp support 
Cardiovascular Systolic blood 
pressure  (mmHg) 
SBP>90  
at all times 









Haematologic Platelet count 
(x109/L) 
>150 100-150 50-99 20-49 <20 
GIT Bilirubin (mol/L) <20 20-32 33-101 102-204 >204 
CNS GCS score 15 13-14 10-12 6-9 3-5 




<0.5 for 2 hours 
171-300 301-440 >440 
 
Abbreviations: CNS, central nervous system; GCS, Glasgow Coma Scale; GIT, 
gastrointestinal; Fi02, inspired oxygen concentration; LPM, litres per minute of oxygen; 
Pa02, arterial partial pressure oxygen concentration; SBP, systolic blood pressure; Sp02 , 

































Table 2. Characteristics of Emergency Department (ED) patients with suspected sepsis 
that received either 10mL/kg of 0.9% NaCl (Isotonic) or 5mL/kg of 3% NaCl 
(Hypertonic).  
 
Data is presented as either median [Q1-Q3], mean (95% confidence interval) or number 
(percentage). * Body weight was available for 26 in the isotonic group and 33 in the 
hypertonic group. # Fisher’s exact test across groups. ^ Time from ED admission to 
delivery of intervention fluid.  
Characteristic Isotonic group 
(n=31) 




Age (years) 45 (39-52) 41 (35-47) 0.83 
Male, n (%) 18 (58) 21 (62) 0.76 
Body weight (kg)* 89 [75-95] 85 [70-95] 0.81 
CCS 0 [0-1] 0 [0-1] 0.45 
Discharge diagnosis, n (%) 







    Suspected infection 9 (29) 11 (32) - 
    Confirmed infection 19 (61) 20 (59) 0.96# 
Admission parameters    
   Heart rate (bpm) 104 (97-111) 102 (97-108) 0.58 
   Respiratory rate (bpm) 21 (19-23) 22 (20-23) 0.50 
   Temperature (oC) 38.3 (37.9-38.7) 38.2 (37.8-38.6) 0.65 
   GCS 15 (15-15) 15 (15-15) - 
   MAP (mmHg) 92 (86-98) 90 (86-95) 0.67 
   WBCC (x109/L) 10.6 [8.9-14.0] 12.7 [10-17] 0.16 
SOFA score in ED 0 [0-1] 0 [0-1] 0.33 
C-reactive protein (mg/mL) 97 [13-180] 99 [38-150] 0.91 
Lactate (mmol/L) 1.5 [1.0-2.1] 1.4 [0.9-2.2] 0.96 
Creatinine (µmol/L) 75 (69-81) 77 (70-84) 0.66 
















Abbreviations: CCS, Charlson Comorbidity Score; GCS, Glasgow Coma Score; MAP, mean 
arterial blood pressure; SOFA, sequential organ failure assessment; WBCC, white blood 


















Table 3. Clinical variables (mean (95% confidence interval)) of Emergency Department 
patients with suspected sepsis that received either 10mL/kg of 0.9% NaCl (Isotonic) or 
5mL/kg of 3% NaCl (Hypertonic), measured at baseline (T0), 1 hour after start of fluid 
intervention (T1), and then 3 hours (T3) and 12-24 hours (T24) later.  
 
 
P values are for differences between groups in change from baseline.  
 
  
Variable n T0 n T1 n T3 n T24 
Heart rate (bpm) 
        
   Isotonic 30 104 (97-111) 30 98 (92-104) 24 93 (87-100) 24 85 (79-91) 
   Hypertonic 34 102 (96-108) 31 95 (89-102) 27 87 (87-99) 26 82 (76-88) 
   P value    0.80  0.85  0.61 
Mean arterial pressure (mmHg) 
        
   Isotonic 30 92 (86-98) 30 87 (82-93) 24 86 (80-92) 24 85 (80-90) 
   Hypertonic 34 90 (86-95) 31 88 (82-94) 27 86 (80-91) 25 91 (85-96) 
   P value    0.43  0.88  0.075 
Haemoglobin (g/L) 
        
   Isotonic 30 143 (137-150) 25 133 (125-141) 17 139 (131-146) 23 131 (123-139) 
   Hypertonic 33 142 (137-147) 24 132 (127-137) 22 132 (127-137) 21 131 (125-136) 
















Table 4. Concentrations (geometric mean, 95% CI) of endothelial activation, glycocalyx 
shedding and inflammation biomarkers in Emergency Department patients with 
suspected sepsis that received either 10mL/kg of 0.9% NaCl (Isotonic) or 5mL/kg of 3% 
NaCl (Hypertonic) measured at baseline (T0), 1 hour after start of fluid intervention 
(T1), and then 3 hours (T3) and 12-24 hours (T24) later.  Comparison between groups 
in change from T0 (fold change (95% CI) is also provided.  
 Biomarker concentration (geometric mean, 95% CI) --------------------------- Fold change (95% CI) from T0 ------------------- 
T0 T1 T3 T24 T1 P T3 P T24 P 
Syndecan-1 
(ng/mL) 
          
   Isotonic 1.5 (1.2-1.9) 1.2 (1.0-1.6) 1.4 (1.0-2.0) 2.0 (1.6-2.5) 0.8 (0.7-0.9)  1.0 (0.9-1.2)  1.3 (1.2-1.5)  
   Hypertonic 1.4 (1.1-1.8) 1.4 (1.1-1.8) 1.5 (1.1-2.0) 2.0 (1.5-2.7) 1.0 (0.9-1.1) 0.012 1.1 (1.0-1.3) 0.41 1.5 (1.3-1.7) 0.42 
Hyaluronan 
(ng/mL) 
          
   Isotonic 5.9 (3.6-9.6) 14.7 (10.3-21.1) 15.3 (10.4-22.4) 26.0 (16.4-41.3) 2.5 (1.7-3.7)  2.6 (1.7-3.9)  4.1 (2.8-6.1)  
   Hypertonic 4.8 (2.5-9.1) 20.2 (13.8-29.7) 11.8 (6.7-20.5) 15.2 (8.5-27.4) 3.9 (2.7-5.7) 0.11 2.7 (1.8-4.0) 0.92 3.4 (2.3-5.0) 0.49 
Interleukin-6 
(pg/mL) 
          
   Isotonic 77 (39-153) 62 (32-120) 65 (28-151) 38 (18-78) 0.8 (0.5-1.2)  0.8 (0.5-1.3)  0.5 (0.3-0.8)  
   Hypertonic 69 (36-133) 62 (31-125) 48 (24-96) 36 (16-83) 0.9 (0.6-1.3) 0.73 0.7 (0.4-1.0) 0.43 0.4 (0.3-0.6) 0.44 
Interleukin-8 
(pg/mL) 
          
   Isotonic 41 (25-66) 41 (28-58) 47 (27-83) 50 (32-80) 1.0 (0.7-1.4)  1.2 (0.9-1.6)  1.2 (0.9-1.6)  
   Hypertonic 20 (12-34) 23 (13-39) 23 (14-40) 28 (18-46) 1.1 (0.8-1.5) 0.79 1.2 (0.8-1.6) 0.91 1.3 (0.9-1.8) 0.65 
Interleukin-10 
(pg/mL) 
          
   Isotonic 1.9 (0.6-6.3) 1.3 (0.4-4.2) 0.7 (0.2-2.2) 0.4 (0.2-0.9) 0.7 (0.3-1.9)  0.3 (0.1-1.0)  0.1 (0.0-0.3)  
   Hypertonic 0.5 (0.2-1.3) 0.5 (0.2-1.3) 0.8 (0.3-2.1) 0.5 (0.2-1.4) 0.9 (0.3-2.8) 0.72 1.2 (0.4-3.5) 0.10 0.8 (0.3-2.6) 0.006 
NGAL      
(ng/mL) 
          
   Isotonic 114 (91-142) 103 (84-126) 119 (93-151) 144 (91-230) 0.9 (0.7-1.3)  1.1 (0.7-1.5)  1.3 (0.9-1.9)  
   Hypertonic 109 (80-149) 100 (67-150) 95 (63-142) 167 (121-231) 0.9 (0.7-1.3) 0.94 0.9 (0.7-1.3) 0.65 1.5 (1.1-2.1) 0.57 
Resistin 
(ng/mL) 
          
   Isotonic 31 (25-39) 28 (22-35) 33 (27-40) 42 (30-57) 0.9 (0.8-1.0)  1.1 (0.9-1.2)  1.4 (1.2-1.6)  
   Hypertonic 36 (29-46) 34 (27-44) 31 (24-40) 42 (31-57) 1.0 (0.9-1.1) 0.45 1.0 (0.8-1.1) 0.32 1.2 (1.1-1.4) 0.15 
sICAM-1 
(μg/mL) 
          
   Isotonic 2.2 (0.8-6.4) 1.9 (0.7-5.2) 0.9 (0.3-2.6) 2.1 (0.7-6.7) 0.9 (0.6-1.2)  0.8 (0.5-1.1)  1.0 (0.7-1.5)  
   Hypertonic 0.3 (0.2-0.6) 0.4 (0.2-0.7) 0.4 (0.2-1.0) 0.3 (0.2-0.7) 1.1 (0.8-1.5) 0.32 1.2 (0.9-1.7) 0.06 1.0 (0.7-1.4) 0.89 
sVCAM-1 
(μg/mL) 


















Abbreviations: NGAL, neutrophil gelatinase-associated lipocalin; sICAM-1, soluble 
intercellular adhesion molecule-1; sVCAM-1, soluble vascular adhesion molecule-1 
 
  
   Isotonic 6.5 (2.2-19.5) 5.6 (2.0-16.2) 2.9 (1.0-8.3) 6.0 (1.8-19.3) 0.9 (0.6-1.2)  0.8 (0.6-1.1)  1.0 (0.7-1.4)  
















Table 5. Number of participants that received either 10mL/kg of 0.9% NaCl (Isotonic) 
or 5mL/kg of 3% NaCl (Hypertonic) with organ failure detected in the Emergency 
Department (ED) or on day 1 or 2 of hospitalisation. Organ failure for each category was 
defined as a Sequential Organ Failure Assessment (SOFA) score >0.  
 
 In ED Day 1 Day 2 
Cardiovascular failure     
   Isotonic group    
      Yes 0 4 2 
      No 27 22 17 
   Hypertonic group    
      Yes 2 0 1 
      No 25 27 21 
   P value 0.091 0.014 0.46 
Hematologic failure  
   
   Isotonic group    
      Yes 4 8 6 
      No 23 18 13 
   Hypertonic group    
      Yes 3 2 4 
      No 24 25 18 
   P value 0.69 0.026 0.32 
Respiratory failure  
   
   Isotonic group    
      Yes 5 7 2 
      No 22 19 17 
   Hypertonic group    
      Yes 5 7 3 
      No 22 20 19 
   P value - 0.93 0.76 
Gastrointestinal failure  
   
   Isotonic group    
      Yes 2 2 1 
      No 25 24 18 
   Hypertonic group    
      Yes 5 6 3 
      No 22 21 19 
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